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Living Renal Donors:
Optimizing the Imaging
Strategy—Decision- and
Cost-effectiveness Analysis1
PURPOSE: To determine the most cost-effective strategy for preoperative imaging
performed in potential living renal donors.
MATERIALS AND METHODS: In a decision-analytic model, the societal cost-
effectiveness of digital subtraction angiography (DSA), gadolinium-enhanced mag-
netic resonance (MR) angiography, contrast material–enhanced spiral computed
tomographic (CT) angiography, and combinations of these imaging techniques was
evaluated. Outcome measures included lifetime cost, quality-adjusted life-years
(QALYs), and incremental cost-effectiveness ratios. A base-case analysis was per-
formed with a 40-year-old female donor and a 40-year-old female recipient.
RESULTS: For the donor, MR angiography (24.05 QALYs and $9,000) dominated all
strategies except for MR angiography with CT angiography, which had an incre-
mental ratio of $245,000 per QALY. For the recipient, DSA and DSA with MR
angiography yielded similar results (10.46 QALYs and $179,000) and dominated all
other strategies. When results for donor and recipient were combined, DSA domi-
nated all other strategies (34.51 QALYs and $188,000). If DSA was associated with
a 99% specificity or less for detection of renal disease, MR angiography with CT
angiography was superior (34.47 QALYs and $190,000).
CONCLUSION: For preoperative imaging in a potential renal donor, DSA is the most
cost-effective strategy if it has a specificity greater than 99% for detection of renal disease;
otherwise, MR angiography with CT angiography is the most cost-effective strategy.
© RSNA, 2002
Before a potential living renal donor donates a kidney, he or she undergoes an extensive
work-up that includes an interview, physical examination, laboratory tests, and ultra-
sonography (US). A detailed radiologic examination of the kidneys concludes this work-up
(1–6). The purpose of the radiologic examination is to determine the number, location,
and length of the renal arteries and to detect anomalies or diseases of the renal vasculature.
In addition, it is used to screen for renal disease that may have escaped detection during
an earlier examination (1,3,6–8). The transplantation team uses this information to decide
whether or not it is safe for the potential donor to undergo removal of one kidney.
Furthermore, the team can decide which kidney to use, on the basis of findings in regard
to the renal vasculature and on the basis of the presence of abnormalities (9–12).
At present, imaging at Erasmus MC Rotterdam, the Netherlands, includes intraarterial
digital subtraction angiography (DSA) for the examination of the renal arteries, and
immediately after, urography is performed for screening the urinary system. DSA with
urography is known to be an accurate method, but it requires catheterization, the use of
iodine-containing contrast material, and exposure of the patient to ionizing radiation
(13,14). Furthermore, DSA is an expensive technique (15), and with the current strategy,
only limited information about the venous anatomy is obtained. This information could
be important, especially if nephrectomy is performed laparoscopically.
To overcome the drawbacks of the presently used imaging, other techniques have been
proposed to replace it. Researchers in a number of studies have assessed the accuracy and
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feasibility of alternative techniques, such
as gadolinium-enhanced magnetic reso-
nance (MR) angiography (7,16–19) or
computed tomographic (CT) angiogra-
phy (20–27). These techniques can de-
pict both the arterial and venous vascu-
lature and the collecting system and
parenchyma. MR angiography accurately
depicts the anatomy of the vasculature,
but mild forms of fibromuscular dyspla-
sia may be missed (7). CT angiography
has capabilities similar to those of MR
angiography, but CT angiography has a
higher resolution than does MR angiog-
raphy and is, furthermore, technically
more robust. The disadvantages of CT an-
giography, however, are that the patient
is exposed to ionizing radiation and that
iodinated contrast material is needed.
Nonetheless, both MR angiography and
CT angiography are less expensive than
DSA (19).
To our knowledge, only two studies
were conducted in which CT angiogra-
phy and gadolinium-enhanced MR an-
giography were compared (28,29). In
these studies, however, the techniques
were compared in regard to the depiction
of only arterial and venous anatomy. Fur-
thermore, the currently used imaging
strategies vary among centers at which
transplantation is performed (4). This
variation in the use of imaging strategies
indicates the prevailing uncertainty as to
what the optimal strategy is and, thus,
emphasizes the need for further investi-
gation of those that are available. Thus,
the purpose of our study was to deter-
mine the most cost-effective strategy for
preoperative imaging performed in po-
tential living renal donors.
MATERIALS AND METHODS
Model
A decision model comparing various
strategies used for screening potential re-
nal donors was developed from the soci-
etal perspective to evaluate the morbid-
ity, mortality, and costs to both renal
donors and renal recipients (30). The
strategies we considered (Table 1) were
DSA with urography (ie, the current strat-
egy), MR angiography, spiral CT angiog-
raphy, and combinations of these imag-
ing techniques.
To compare these imaging strategies,
we modeled the prevalence of vascular
anomalies and kidney disease, the prob-
ability of detection of anomalies and dis-
ease, and long-term outcomes. We (Y.S.L.,
K.V., M.G.M.H.) developed a Markov
process model to estimate the quality-
adjusted life expectancy and lifetime cost
for both renal donors and recipients. Fig-
ure 1 shows a schematic representation
of the decision model. The model starts
with imaging performed in the donor,
when the donor has already undergone
the first phases of the work-up, which
included the interview, physical exami-
nation, laboratory tests, and US.
A diagnosis of renal disease was deter-
mined when an abnormality in the reno-
vascular system, the kidney, or the col-
lecting system and distal urinary tract
was seen on the image. Renovascular
anomalies and abnormalities that do not
have a major effect on the prognosis of
the patient, such as unilateral cysts, cal-
culi, and parenchymatous lesions, were ex-
cluded from our determination of the di-
agnosis of renal disease. If imaging findings
suggested renal disease, no transplanta-
tion was performed. However, because of
inaccuracy, renal disease may not have
been present, which constituted a missed
opportunity. If imaging findings did not
reveal renal disease, transplantation was
performed, with its associated morbidity
and mortality for both donor and recipi-
ent. If unilateral renal disease was not
detected during imaging performed in
the donor, the donor may have one dis-
eased kidney after transplantation, or the
recipient may receive a diseased trans-
plant. In the case of bilateral renal dis-
ease, both the donor and the recipient
have a diseased kidney after transplanta-
tion.
With the model, we considered that the
presence of renovascular anomalies (ie,
multiple renal arteries or veins, early arte-
rial branching) influences the choice of
which kidney to transplant and increases
the duration of the surgery, which results
in higher costs.
Furthermore, we also considered that a
donor with renal disease diagnosed dur-
ing the radiologic examination will be
treated and may need dialysis later in life.
A donor who has one diseased kidney
after transplantation and a recipient who
receives a diseased kidney will develop
clinical renal disease at a later point in
life and may require dialysis. A potential
recipient whose donor received—cor-
rectly or incorrectly—a diagnosis of renal
disease will continue to receive treatment
with dialysis. A recipient whose trans-
plant fails returns to dialysis.
Data Sources and Assumptions
Background information.—A systematic
review of the literature pertaining to liv-
ing renal donor transplantation was per-
formed. The search strategy we used to
retrieve the literature-based information
was as follows: living donors AND kidney
NOT cadaver NOT developing countries
NOT DNA NOT Histocompatibility test-
ing NOT reoperation NOT Kidney/*his-
tology NOT Kidney Calculi/*etiology
NOT liver NOT drug therapy NOT pan-
creas transplantation NOT antibodies.
Additional data were obtained from our
TABLE 1
Strategies Considered for the Study
Strategy Protocol
DSA* Current imaging strategy, DSA with urography, was performed
MR angiography† Performed with enhancement with gadolinium-based contrast
material
Spiral CT angiography† Performed with contrast enhancement
DSA with MR angiography‡ Current imaging strategy, performed first, and MR
angiography were performed during one visit
MR angiography, DSA†‡ If results of MR angiography were inconclusive, the current
imaging strategy was performed during second visit
MR angiography with CT
angiography§
MR angiography, performed first, and CT angiography were
performed during one visit
No test, always transplantation No test, and transplantation was always performed
No test, no transplantation No test, and transplantation was not performed
* Standard of reference for detection of renal disease; we assumed DSA did not fail technically.
† If the donor had any contraindications to MR angiography (eg, claustrophobia, metal im-
plants) or if MR angiography or CT angiography failed technically, the donor underwent the
current imaging strategy.
‡ If both MR angiography and DSA were performed but MR angiography failed technically,
results of only DSA were considered.
§ If MR angiography was contraindicated, only CT angiography was performed, and when the
latter failed technically, DSA was performed. When both MR angiography and CT angiography
were performed, but one failed technically, it was assumed that the transplantation team relied on
the results of the successful imaging strategy. If both failed, DSA was performed.
 Reference strategy.
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own clinical data and from the Dutch
statistics. We (Y.S.L., M.C.J.M.K.) per-
formed a cost analysis for the local set-
ting. Tables 2–4 present the parameters
of the model, with the values used in the
base-case analysis and the ranges over
which these values were varied in the
sensitivity analyses. (More detail on the
computation of the test characteristics,
probabilities, and costs is available on re-
quest.)
Tests and test characteristics of the vari-
ous strategies.—Published reports were re-
viewed by the first author (Y.S.L.) con-
cerning DSA performed with a low-
osmolar contrast agent administered
through intraarterial injection into the
femoral artery, MR angiography per-
formed with an intravenously adminis-
tered gadolinium-based contrast agent,
or CT angiography performed with an
intravenously administered low-osmolar
contrast agent. Studies of researchers
were included in this review if they re-
ported sensitivity and specificity for renal
disease or renal anomalies.
We considered the currently used strat-
egy (ie, DSA with urography) as the refer-
ence standard for detection of renal disease
and surgery as the reference standard for
detection of renovascular anomalies. Even
though the sensitivity and specificity of
DSA for detection of renal disease are
probably not 100%, DSA is at present the
best possible reference standard since dis-
ease cannot be detected during surgery.
For detection of anomalies, we consid-
ered surgery as the reference standard. A
disadvantage of choosing surgery as the
reference standard is, however, that only
one of the two kidneys is seen during
surgery, which is most likely the one
with the least complicated anatomy.
We (Y.S.L., M.G.M.H.) estimated the
sensitivity and specificity for detecting
renal disease and the sensitivity for de-
tecting anomalies associated with gado-
linium-enhanced MR angiography and
contrast-enhanced spiral CT angiogra-
phy on the basis of data from published
studies (18,19,33,34). The specificity for
detection of anomalies was not used, be-
cause false-positive test results have no
consequences since costs are incurred
only if anomalies are present. Imaging
characteristics are presented in Table 2.
Prevalence of anomalies and kidney dis-
ease.—On the basis of data from large
studies in regard to the preoperative ex-
amination of renal donors (13,26,36–38),
we (Y.S.L., M.G.M.H.) estimated the prev-
alence of renal anomalies and renal dis-
ease in potential living renal donors (Ta-
ble 3).
Donor risks.—We (Y.S.L., M.G.M.H.) es-
timated the morbidity and mortality asso-
ciated with various strategies (31,32,35)
and the morbidity associated with laparo-
scopic nephrectomy (39) on the basis of
data from the literature. Since a reliable
estimate for mortality associated with lapa-
roscopic donor nephrectomy was not
available, it was assumed to be the mortal-
ity associated with open nephrectomy (6).
Long-term survival among renal donors
was estimated on the basis of Dutch mor-
tality statistics (55), since on the basis of
data in the literature, we determined that
this is the same as or better than the sur-
vival of the general population (42).
If, however, a renal donor has a dis-
eased kidney after transplantation, and
this diseased kidney has escaped detec-
tion during the diagnostic work-up, we
Figure 1. Schematic representation of the structure of the model. RTx  renal transplantation, D  donor, R  recipient.
Volume 226  Number 1 Living Renal Donors: Optimizing the Imaging Strategy  55
R
a
d
io
lo
gy
TABLE 2
Estimates for Model Variables: Characteristics of Imaging Examinations
Variable Baseline Value Range Reference No. or Other Source
DSA
Sensitivity for renal disease 100 82–100 . . .*
Specificity for renal disease 100 95–100 . . .*
Sensitivity for renal anomalies 82 75–91 13, 15
Complication rate 1.7 0.5–3.0 31, 32
Mortality rate 0.033 0.029–0.162 31, 32
Technical failures 0 Not available Expert opinion (M.G.M.H.)
MR angiography
Sensitivity for renal disease 93 90–100 33
Specificity for renal disease 90 88–100 33
Sensitivity for renal anomalies 82 71–100 18, 19
Complication rate 0 0–0.031 . . .†
Mortality rate 0 0–0.0009 . . .†
Contraindication for MR angiography 6.7 3.0–10.0 . . .‡
Technical failures 2.5 1.0–4.0 16, 19
CT angiography
Sensitivity for renal disease 95 90–100 23, 34
Specificity for renal disease 98 97–100 23, 34
Sensitivity for renal anomalies 83 65–99 21, 22, 24, 26
Complication rate 0.031 0.002–0.062 35
Mortality rate 0.0009 0.0003–0.0026 35
Technical failures 1.9 0.5–3.5 25
DSA with MR angiography
Sensitivity for renal disease 100 82–100 . . .§
Specificity for renal disease 100 95–100 . . .§
Sensitivity for renal anomalies 82 82–95 . . .
Complication rate 1.7 0.5–3.0 . . .#
Mortality rate 0.033 0.029–0.162 . . .**
Contraindication for MR angiography 6.7 3.0–10.0 . . .‡
Technical failures 2.5 1.0–4.0 16, 19
MR angiography, DSA if MR angiography results inconclusive
Sensitivity of MR angiography for renal disease 95 90–99 . . .††
Specificity of MR angiography for renal disease 95 90–99 . . .††
Sensitivity of MR angiography for renal anomalies 82 82–95 . . .‡‡
Complication rate when only MR angiography was
performed 0 0–0.031 . . .†
Mortality rate when only MR angiography was performed 0 0–0.0009 . . .†
Contraindication for MR angiography 6.7 3.0–10.0 . . .‡
Technical failures of MR angiography 2.5 1.0–4.0 16, 19
Inconclusive results of MR angiography 30 10–50 . . .§§
Sensitivity of DSA with MR angiography for renal disease 100 82–100 . . . 
Specificity of DSA with MR angiography for renal disease 100 95–100 . . . 
Sensitivity of DSA with MR angiography for renal anomalies 82 82–95 . . . 
Complication rate 1.7 0.5–3.0 . . .#
Mortality rate 0.033 0.029–0.162 . . .**
MR angiography with CT angiography##
Sensitivity for renal disease 100*** Not available††† 23, 33, 34
Specificity for renal disease 100*** Not available††† 23, 33, 34
Sensitivity for renal anomalies‡‡‡ 83 65–99 21, 22, 24, 26
Complication rate 0.031 0.002–0.062 . . .#
Mortality rate 0.0009 0.0003–0.0026 . . .**
Contraindication for MR angiography 6.7 3.0–10.0 . . .‡
Note.—All data are percentages.
* DSA was assumed to be the reference standard.
† It was assumed that MR angiography did not involve any risks.
‡ Paul Nederkoom, MD, written communication, August 2000.
§ The sensitivity and specificity of DSA were used.
 The sensitivity for the detection of anomalies with MR angiography was used; however, since MR angiography can depict venous anomalies, the
sensitivity for detection of anomalies with this strategy was expected to be higher than that of DSA. Therefore, a sensitivity analysis was performed with
the baseline estimate as the lower value and an estimated value of 95% as the upper value.
# Complication rates of the combination of strategies were computed by summing the complication rates of each strategy.
** Mortality rates of the combination of strategies were computed as follows: mortality of the first imaging examination performed  (1  mortality
of the first imaging examination performed)  mortality of the second imaging examination performed.
†† No data were available. Estimates were determined on the basis of the assumption that these values were higher than those of the characteristics
of MR angiography.
‡‡ The sensitivity of MR angiography was used.
§§ Because of inconclusive results of MR angiography, DSA was performed.
  The values of the characteristics (baseline and sensitivity analysis estimates) of DSA with MR angiography were used.
## Data are those that apply when both MR angiography and CT angiography were technically successful.
*** Technically, these values were between 99% and 100%, but when rounded, they were 100%.
††† Values of characteristics of MR angiography and CT angiography were varied separately. Because the same variables were used with MR
angiography with CT angiography, the values of the characteristics of this strategy were also varied over a plausible range.
‡‡‡ The sensitivity for depiction of anomalies with CT angiography was used.
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assumed a 25% chance that the donor
would need renal replacement therapy
after 15 years. If a donor receives a diag-
nosis of renal disease during the work-up,
the donor is treated for the disease. On
the basis of our own clinical data, we
estimated that 5% (one of 19) of these
donors who receive a diagnosis of disease
and are treated would require dialysis af-
ter 15 years because of untreatable or re-
current disease. The survival rate for a
donor who requires dialysis after 15 years
was assumed to be the same as that of the
general population for the first 15 years
and to be the same as that of patients
receiving dialysis after this period. Data
regarding donor risks are presented in Ta-
ble 3.
Recipient risks.—Morbidity associated
with renal implantation was estimated
on the basis of our own clinical data. We
(Y.S.L., J.N.M.I.) estimated surgical mor-
tality to be 1%. Relative risks of mortality
for recipients of a renal transplant (43–
46) and for patients receiving both CAPD
and hemodialysis (47) compared with
the mortality of the general Dutch pop-
ulation (55) were computed on the basis
of data from the literature (43–47). To
determine a relative risk of mortality for
dialysis, the relative risks of CAPD and
hemodialysis were averaged according to
the prevalences of both methods among
patients receiving dialysis in the Nether-
lands (48). We also computed transplant
failure rates on the basis of data from the
literature in regard to graft survival (43–
45,49,50). We assumed that recipients
who received a diseased transplant had a
survival rate that was the same as that of
recipients of a nondiseased transplant for
the first 10 years, and we assumed that
they would need dialysis after this pe-
riod. Table 3 includes the data on recipi-
ent risks.
Quality weights.—Because renal donors
are healthy individuals, their quality-of-
life estimate was considered to be 1.
However, for donors who need dialysis
after 15 years, the estimate was assumed
to be 1 for the first 15 years and the same
as the estimate for patients receiving di-
alysis after this period. The quality-of-life
estimates for transplant recipients and
patients receiving dialysis were obtained
from the literature (51,52) (Table 4). We
assumed that the quality weight of a re-
cipient who received a diseased trans-
plant was the same as the quality weight
of a transplant recipient for the first 10
years and the same as the quality weight
associated with dialysis after this period.
Costs.—To compute costs of imaging
and transplantation, the Dutch guide-
lines for computing costs in health care
were used (56). Costs were determined
from the societal perspective and in-
cluded both medical and nonmedical
costs (Table 4).
Direct medical costs included costs for
personnel, materials, equipment, sup-
porting departments, housing and over-
head, and hospitalization and consulta-
tions. For the computations, we obtained
data from the Departments of Radiology
and of Surgery and the Finance Depart-
ment of our center. For the computation
of equipment costs, we used the annuiti-
zation method, with a discount rate of
3% (30). Costs for hospitalization and
consultations were computed by using
prices from the Dutch guidelines and
data from our center.
Furthermore, we (Y.S.L., M.C.J.M.K.)
computed direct nonmedical costs of the
imaging strategies and of surgery of both
donor and recipient, which included
travel expenses and time costs. On the
basis of the Dutch guidelines, travel ex-
penses were calculated as travel distance
TABLE 3
Estimates for Model Variables: Prevalences and Risks
Variable
Baseline
Value Range
Reference No.
or Other Source
Prevalence among donors
Renal anomalies (%)* 44.7 41.5–49.4 13, 26, 36
Unilateral anomalies (% of all anomalies) 75 70–79 36–38
Venous anomalies (% of all anomalies) 25 15–35 26
Renal disease (%) 6.3 3.2–10.6 13, 26, 36,
present study
Unilateral disease (% of all diseases) 80 70–90 36
Donor risks
At surgical operation
Morbidity (% of complications) 14 5–20 39
Mortality (%) 0.03 0.00–0.05 39, 40, 41
In the long term
Relative risk of mortality compared with that of
general population 1 0.39–1.50 42
Dialysis-free survival if renal disease was present 15 10–20 . . .†
Proportion of donors developing end-stage
renal disease in whom disease was not
detected (%)‡ 25 0–100 . . .‡
Proportion of donors developing end-stage
renal disease in whom disease was detected
(%) 5.3 0–10
Expert opinion
(W.W.)
Recipient risks
At surgical operation
Morbidity (% of complications) 33 10–50 Expert opinion
(J.N.M.I.)
Mortality (%) 1 0.5–3.0 Expert opinion
(J.N.M.I.)
In the long term
Relative risk of mortality of renal transplant
recipient after transplantation, compared
with that of general population
1 y 9.7 7.5–35.5 43–46
3 y 3.6 Not available 43–46
5 y 5.0 4.8–8.7 43–46
Relative risk of mortality of patient receiving
CAPD, compared with that of general
population 14 11–16 47
Relative risk of mortality of patient receiving
hemodialysis, compared with that of
general population 21 18–24 47
Proportion of patients receiving CAPD among
total of those receiving dialysis (%) 28 10–50 48
Graft failure rate after transplantation
1 y 0.072 0.020–0.092 43–45, 49, 50
3 y 0.050 0.026–0.044 43–45, 49, 50
5 y 0.034 0.039–0.048 43–45, 49, 50
Note.—CAPD  continuous ambulatory peritoneal dialysis.
* Renal anomalies include multiple renal arteries, early arterial branching, and multiple renal
veins.
† Dialysis-free survival for a donor was assumed to be 15 years.
‡ Since the probability that dialysis was needed in donors with undetected disease was unknown,
it was assumed to be 25%, and it was varied over a wide range.
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multiplied by a fixed cost per kilometer.
Time costs were computed by using the
estimated time required to undergo the
imaging and the surgery and the average
sex- and age-specific wage rates (57). We
obtained wage rates from the Central Bu-
reau of Statistics, Voorburg/Heerlen, the
Netherlands.
We assumed that annual direct medi-
cal costs for a donor after transplantation
were the same as the costs of an outpa-
tient visit (56). Annual direct medical
costs of receiving a renal transplant and
yearly costs of CAPD and hemodialysis
were computed on the basis of data from
the literature (53,54). For the annual di-
rect nonmedical costs, we computed
travel expenses and time costs in the
same manner as we computed these costs
for the imaging and the surgery. All costs
were standardized to Dutch guilders for
the year 2000 and subsequently were
converted to U.S. dollars for the year
2000 (exchange rate: 10,000 Dutch guil-
ders  $4,186  4,545 euros).
Indirect costs were not considered in
the computation of costs. Production loss
for a donor does not occur because the
general health of a donor was assumed to
be the same before and after donation.
For the recipient, production loss was as-
sumed to be negligible, since recipients’
pre- and posttransplantation employ-
ment rates did not differ significantly
(58).
Analyses
The lifetime costs and quality-adjusted
life-years (QALYs) gained were calculated
for each strategy. First, these data were
calculated for the donor and recipient
separately, and subsequently, the total
lifetime cost and total QALYs were calcu-
lated for each strategy for donor and re-
cipient combined. Both QALYs and costs
were discounted at 3% (range, 0%–10%)
per year. On the basis of costs and QALYs
for donor and recipient considered sepa-
rately, we computed incremental cost-ef-
fectiveness ratios. To enable decision
making for both donor and recipient
combined, we summed the costs for the
recipient and donor, summed their re-
spective QALYs, and calculated the corre-
sponding incremental cost-effectiveness
ratios.
Strategies that were dominated or ex-
tended dominated were eliminated from
further consideration. A strategy was
considered to be dominated by another
strategy if costs were higher, whereas
QALYs were lower than they were for the
other strategy. A strategy was considered
to be extended dominated by another
strategy if it had a higher incremental
cost-effectiveness ratio and lower QALYs.
A strategy that was both more costly and
more effective was considered to be cost
effective if its incremental cost-effec-
tiveness ratio did not exceed the thresh-
old of society’s willingness to pay for
gaining 1 QALY (R) (59). A recently
published article indicated that R was
$25,000–$400,000 (60).
Since the purchasing power of $1 in
the United States was about the same as
that of 1 Dutch guilder in the Nether-
TABLE 4
Estimates for Model Variables: Quality-of-Life and Cost Estimates
Variable Baseline Value Range Reference No. or Other Source
Quality-of-life estimates
Donor 1 0.9–1.0 . . .*
Renal transplant recipient† 0.84 0.84–0.94 51, 52
Patient receiving CAPD† 0.56 0.56–0.79 51, 52
Patient receiving hemodialysis† 0.43 0.43–0.63 51, 52
Cost estimates for year 2000 ($)
Mortality 2,152 1,076–3,228 . . .‡
Imaging
Current strategy, DSA with urography 440 362–597 Present study
MR angiography 469 333–604 Present study
CT angiography 232 168–299 Present study
Complications§ 627 313–940 Present study
Transplantation
Donor nephrectomy 6,104 5,647–6,563 Present study
Extra costs per surgical operation when anomalies were present
and detected during imaging 88 44–152 Present study
Extra costs per surgical operation when anomalies were present
but not detected during imaging 220 111–379 Present study
Complications of donor nephrectomy# 1,567 940–2,194 Present study
Recipient implantation 6,412 5,954–6,871 Present study
Complications of recipient implantation** 3,133 1,567–4,701 Present study
Costs per year of life
Donor who has donated 84 57–149 . . .††
Patient receiving CAPD 25,327 16,802–33,520 53, 54
Patient receiving hemodialysis 40,401 27,933–53,009 53
Renal transplant recipient, 1st year after transplantation 3,843 1,374–5,553 53, expert opinion (W.W.)
Renal transplant recipient, subsequent years after
transplantation as long as donor is alive without dialysis 2,866 1,288–5,466 53, expert opinion (W.W.)
Note.—CAPD  continuous ambulatory peritoneal dialysis.
* Donors were assumed to be in perfect health.
† Quality estimates were obtained from the patient populations by using the time trade-off technique.
‡ It was assumed that mortality resulted within 2 days of hospitalization in the intensive care unit prior to death.
§ It was assumed that complications required 2 days of hospitalization.
 Costs were computed by considering the prevalences of unilateral and bilateral disease.
# It was assumed that complications required 5 days of hospitalization.
** It was assumed that complications required 10 days of hospitalization.
†† It was assumed that donor check-up costs were similar to costs of a visit to the outpatient clinic of a university hospital.
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lands in the year 2000, we used an R of
100,000 Dutch guilders ($41,000) as our
baseline estimate and varied R from
25,000 to 400,000 Dutch guilders
($10,000–$168,000) in our sensitivity
analyses. All analyses were performed
with statistical software (DATA 3.5.7;
TreeAge Software, Williamstown, Mass).
A base-case analysis was performed with
a 40-year-old female donor and a 40-
year-old female recipient. We performed
one-way sensitivity analyses to test if our
baseline results were sensitive to varying
all estimates over plausible ranges. In ad-
dition, we performed several two-way
sensitivity analyses.
RESULTS
Base-Case Analysis
The lifetime costs, QALYs, and incre-
mental cost-effectiveness ratios in regard
to the donor and recipient considered
separately are shown in Table 5 for our
base-case analysis. With respect to the
donor, QALYs differed very little among
the imaging strategies. The “no test, no
transplantation” reference strategy dom-
inated all other strategies, but since the
donor desires to donate his or her kidney,
we assumed this strategy would not be an
option for the donor. The “no test, no
transplantation” strategy is presented for
comparison purposes only. Of the strate-
gies, MR angiography was associated with
the lowest cost. MR angiography with CT
angiography yielded more QALYs but at
$245,000 per QALY. In regard to the re-
cipient, the QALYs varied more among
the strategies, and the costs were much
higher. From the recipient’s perspective,
the “no test, always transplantation”
strategy dominated all other strategies,
but it would be unethical not to test do-
nors at all (this strategy is also presented
for comparison purposes only). Of the
strategies, DSA and DSA with MR angiog-
raphy dominated all other strategies.
Costs and QALYs for these strategies were
the same, since additionally performing
MR angiography would affect only donor
costs of the imaging and the surgery.
Summation of costs and QALYs of do-
nor and recipient and computation of
incremental cost-effectiveness ratios (Ta-
ble 6) showed that DSA (34.51 QALYs
and $188,000) dominated all other strat-
egies.
Sensitivity Analyses
The results of application of the model
were not sensitive to varying parameters
over a plausible range except for two of
the one-way sensitivity analyses. In one
analysis, in which specificity of DSA was
99% or less, MR angiography with CT
angiography was the most cost effective
from the combined perspective of donor
and recipient (34.47 QALYs and $190,000).
In another analysis, the model proved to
be sensitive to the specificity of CT an-
giography for detection of renal disease:
if specificity was 100%, CT angiography
would be the most cost-effective strategy
(34.52 QALYs and $187,000).
In two-way sensitivity analyses, we
varied both the prevalence of disease and
sensitivity or specificity of MR angiogra-
phy or CT angiography for detection of
renal disease. The analysis for the opti-
mal decision from the combined perspec-
tive of donor and recipient, when sensi-
tivity of MR angiography and prevalence
of disease were varied, is shown in Figure
2. At low prevalences of disease, DSA is
TABLE 5
QALYs, Cost, and Incremental Cost-Effectiveness Ratios
Strategy* QALYs† Cost ($)
Incremental Cost-
Effectiveness Ratio
($ per QALY)‡
Donor
No test, always transplantation 23.98 11,100 Reference strategy
DSA 24.05 9,600 Dominated
DSA with MR angiography 24.05 9,900 Dominated
MR angiography 24.05 9,000 . . .§
MR angiography, DSA if MR angiography results
inconclusive 24.05 9,500 Dominated
CT angiography 24.06 9,300 Extended dominated
MR angiography with CT angiography 24.06 9,800 245,000
No test, no transplantation 24.07 1,200 Reference strategy
Recipient
No test, no transplantation 5.16 425,000 Reference strategy
MR angiography 9.99 200,000 Dominated
MR angiography, DSA if MR angiography results
inconclusive 10.29 186,000 Dominated
CT angiography 10.36 183,000 Dominated
MR angiography with CT angiography 10.42 180,000 Dominated
DSA 10.46 179,000 . . .§
DSA with MR angiography 10.46 179,000 . . .§
No test, always transplantation 10.62 165,000 Reference strategy
* Strategies are listed according to increasing QALYs.
† QALYs were rounded off and may falsely seem similar.
‡ Computed without considering the “no test, no transplantation” strategy and the “no test,
always transplantation” strategy.
§ Strategy associated with lowest cost was used as a reference strategy to compute incremental
cost-effectiveness ratios.
TABLE 6
Cost, QALYs, and Incremental Cost-Effectiveness Ratios
for Donor and Recipient Combined
Strategy* QALYs†
Cost
($)†
Incremental Cost-Effectiveness
Ratio ($ per QALY)‡
No test, no transplantation 29.23 426,000 Reference strategy
MR angiography 34.04 209,000 Dominated
MR angiography, DSA if results
inconclusive 34.35 196,000 Dominated
CT angiography 34.42 192,000 Dominated
MR angiography with CT angiography 34.48 190,000 Dominated
DSA 34.51 188,000 . . .§
DSA with MR angiography 34.51 189,000 Dominated
No test, always transplantation 34.60 176,000 Reference strategy
* Strategies are listed according to increasing QALYs.
† Numbers are based on data from the base-case analysis and therefore may differ from those of
the sensitivity analysis.
‡ Computed without considering the “no test, no transplantation” strategy and the “no test,
always transplantation” strategy.
§ Strategy associated with lowest cost was used as a reference strategy to compute incremental
cost-effectiveness ratios.
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the most cost effective. When prevalence
is slightly higher, MR angiography with
CT angiography is superior. Contrary to
what we would have expected, at high
prevalence of disease, MR angiography is
the most cost effective when its sensitiv-
ity for detection of renal disease is low,
and CT angiography is the most cost ef-
fective when sensitivity of MR angiogra-
phy for disease is high.
When both prevalence of disease and
the sensitivity of MR angiography are
varied in determining the most cost-ef-
fective strategy from the perspective of
the donor (Fig 3), MR angiography is
most cost effective at low prevalence of
disease. When prevalence is slightly
higher, CT angiography is superior, and
if prevalence of disease is high, DSA is
most cost effective. However, if the sen-
sitivity of MR angiography is high, MR
angiography is superior (unless the prev-
alence of disease is 100%).
Age was also varied from 25 to 75 years
for both donor and recipient in a two-
way sensitivity analysis. The DSA strategy
was most cost effective over the entire
age range.
DISCUSSION
The objective of our study was to identify
the most cost-effective strategy for the
preoperative evaluation of living, related,
potential renal donors. On the basis of a
decision- and cost-effectiveness analysis,
we conclude that from the perspective of
the donor, MR angiography is the most
cost-effective strategy, whereas from the
combined perspective of donor and re-
cipient, DSA is the most cost-effective
strategy. If, however, specificity of DSA
for the detection of renal disease is 99%
or less, MR angiography with CT angiog-
raphy is most cost effective from the
combined perspective of donor and re-
cipient.
Several general limitations to our study
should be mentioned. First, the model
was based on multiple data sources. Sec-
ond, much of the information used in
this study was obtained from the litera-
ture and, thus, may be subject to publi-
cation bias. Furthermore, generalizability
is limited because cost data were ob-
tained from only our own center. In ad-
dition, imaging protocols for each of the
techniques, characteristics of both the
donor and recipient population, and ex-
pertise may vary among transplantation
centers.
Limitations more specifically related to
our model included limited availability
of data. No literature data were available
concerning survival with renal disease.
Pozniak and colleagues (26) argued that
fibromuscular dysplasia is relatively sta-
ble in patients older than 40 years and
that most donors are approximately 40
years of age. However, arterial stenosis is
known to progress. Thus, we took into
account the possibility that donors
would need dialysis after a number of
years and varied the estimates over a
wide range to assess possible changes in
results. Also, few data have been pub-
lished that can be used to quantify the
quality of life of renal donors. On the
basis of the available qualitative litera-
ture (61), we assumed the donors were
perfectly healthy. Further research into
the quality of life of renal donors is nec-
essary, however, because preserving the
quality of life of the donor is a high pri-
ority.
Information concerning the test char-
acteristics of the imaging strategies for
detection of renal disease is also lacking.
Most studies report characteristics for de-
tection of arterial anomalies, such as
multiple renal arteries and early arterial
branching. These anomalies, however,
only influence the costs of the surgery
that the donor undergoes because the
length of the surgery is increased. More
important for the radiologic examination
are the sensitivity and specificity with re-
spect to detection of renal disease, since
these influence both costs and QALYs in
regard to both donor and recipient.
Therefore, researchers in future studies
should focus on test characteristics of im-
aging strategies for the detection of renal
disease rather than on test characteristics
of those for the detection of renal anom-
alies.
Several technical implications of our
analyses can be mentioned. First, some of
our results were counterintuitive but, on
reflection, could be explained and helped
us obtain insight into how various factors
could and should contribute to the deci-
sion. For example, counter to our intu-
ition, we found that DSA is the most cost-
effective option at low prevalence of
disease (Fig 2). This can be explained by
the fact that, at low prevalence of disease,
specificity is more influential. A high
transplantation rate is more cost effective
from the combined perspective of both
donor and recipient because of the ben-
efits to the recipient. Because false-posi-
tive results imply no transplantation, a
high specificity is required, and DSA has
the greatest specificity of 100%. At higher
prevalence of disease, sensitivity be-
comes more important, and for the trans-
plantation rate to be high, a high false-
negative rate (implying transplantation),
and thus low sensitivity, is required. This
explains why MR angiography is the
most cost-effective option when preva-
lence of disease is high and sensitivity for
detection of disease is low.
With consideration of only the donor’s
results (Fig 3), it can be seen that the
counterintuitive results from the com-
bined perspective are indeed caused by
the benefit to the recipient (both in terms
of QALY gains and cost savings) through
a higher transplantation rate.
Second, a one-way sensitivity analysis
showed that CT angiography is most cost
effective if its specificity is 100%. Since
results in studies in the literature are con-
tradictory as to the ability of CT angiog-
raphy to depict or exclude fibromuscular
dysplasia (22,26,34,62–64), one can ar-
gue that a specificity of 100% will not be
attainable. However, researchers in all
studies used single–detector row spiral
CT angiographic equipment, and one
might argue that with multi–detector
row spiral CT angiography, a higher spec-
ificity of CT angiography could be deter-
Figure 2. Two-way sensitivity analysis with
varying prevalence of disease and sensitivity of
MR angiography (light gray area) for detection
of disease from the combined perspective of
donor and recipient. On the x axis, prevalence
of renal disease is represented, and on the y
axis, sensitivity of MR angiography for detec-
tion of renal disease is represented. Both were
varied 0%–100%. The areas in the plot repre-
sent the ranges over which a certain strategy is
most cost effective from the combined per-
spective of donor and recipient, when the “no
test, always transplantation” strategy was left
out of the analysis. At low prevalence of dis-
ease, DSA (white area) was the most cost effec-
tive. MR angiography with CT angiography
(dark gray area) was superior if the prevalence
was slightly higher. For high prevalence of dis-
ease, either CT angiography (black area) or MR
angiography was superior depending on the
sensitivity of MR angiography.
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mined. Even if 100% specificity can be
determined, the harmful effects of radia-
tion exposure should also be considered.
Furthermore, although some authors
advocate the use of MR angiography in
addition to DSA to depict venous anom-
alies, the addition of MR angiography to
the imaging strategy cannot be cost effec-
tive, because the additional costs that re-
sult from having to deal with anomalies
during the surgery are less than the cost
of MR angiography. However, in our
analysis we did not take into account the
confidence of the surgeon who per-
formed the transplantation. One would
expect that having imaging data prior to
surgery would enhance the surgeon’s
confidence. Quantification of this in-
creased confidence could translate into
an increase in the surgeon’s quality of
life. If an analysis is performed from the
societal perspective, this should also be
considered. We believed, however, that
including the surgeon’s quality of life
would be extending the analysis too far.
Finally, in the analyses, the “no test,
always transplantation” reference strat-
egy appeared to be the most cost effective
option for the combined perspective of
the donor and the recipient. As has been
stated, however, performing no test at all
in donors would be unethical, since the
transplantation team relies on the find-
ings on the images in planning and per-
forming the surgery (28) and because the
team should not compromise its care for
the safety of the donors (22).
In the analysis of the clinical implica-
tions of our results, we should emphasize
the importance of the perspective used. If
costs and effectiveness of only the donor
were considered, MR angiography would
be best because it is associated with a
lower transplantation rate. To optimize
the recipient’s outcome, it would be best
if the donor underwent DSA or DSA with
MR angiography. When the combined
perspective of donor and recipient was
considered, DSA was the most cost effec-
tive. The outcomes of the recipient may
outweigh those of the donor in this com-
bined result, because, for the recipient,
the difference in QALYs gained varies
more among the strategies.
The choice of how to combine the out-
comes of two subjects, in this case, the
donor and the recipient, is not as straight-
forward as it may seem. According to Hip-
pocrates’s principle of “first do no harm,”
we may believe that the donor’s survival
and quality of life should weigh more in
the overall analysis. According to the util-
ity theory applied in the context of cost-
effectiveness analysis of health care, all
QALYs are considered the same, regardless
of who benefits from the gained QALYs
(57). In accordance with this theory, we
valued a QALY of a donor the same as a
QALY of the recipient. It may, however, be
argued, that a QALY of the donor should
be weighed more heavily than a QALY of
the recipient, because the donor gives up
QALYs for the benefit of the recipient.
Such an argument would be based on the
notion that “losses loom larger than gains”
(65). Altruistic motives of the donor were
not considered in this model, since the de-
sire to donate is extremely difficult, if not
impossible, to quantify.
In conclusion, for the preoperative ra-
diologic examination performed in po-
tential living renal donors, DSA is the
most cost-effective strategy when it is
considered as the reference standard, but
if the specificity of DSA for the detection
of disease is 99% or less, which is proba-
ble, MR angiography with CT angiogra-
phy is the most cost-effective strategy.
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